Alternative Topical Treatment to an Aluminum Chloride Antiperspirant that Provides Prescription Strength Efficacy with Significantly Less Irritation

Paula Hartwig BS, David Swaile PhD, Amy Capretta BS

OBJECTIVE

As reported at the 2006 AAD Annual Meeting, application of an OTC anhydrous "soft solid" antiperspirant (AP) containing a non-Aluminum Chloride active ingredient (Aluminum Zirconium Trichlorohydrex), can deliver statistically similar efficacy to a prescription AP containing aluminum chloride while providing a substantial decrease in patient axillary irritation.

RESULTS

Clinical Efficacy Results

• In both clinical trials, the OTC anhydrous "soft solid" AP (Treatment A) provided statistically similar efficacy to the Prescription Aluminum Chloride AP (Treatment C).

<table>
<thead>
<tr>
<th>Evaluation</th>
<th>Trt</th>
<th>Mean Sweat Collected (mg)</th>
<th>Percent Difference (SS-Rx)/SS%/100%</th>
<th>Confidence Bound*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post Trt 6</td>
<td>A</td>
<td>175</td>
<td>2.6%**</td>
<td>[18.5%]</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>170</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post Trt 6</td>
<td>A</td>
<td>141</td>
<td>-12.7%**</td>
<td>[-1.6%]</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>159</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post Trt 9</td>
<td>A</td>
<td>173</td>
<td>-5.7%**</td>
<td>[5.1%]</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>182</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*For both studies, a confidence bound less than 20% indicates that Treatment A is non-inferior to Treatment C.

Skin Irritation Results

• In both clinical trials, the OTC anhydrous "soft solid" AP provided a statistically significant advantage to the Prescription Aluminum Chloride AP.

CONCLUSIONS

• Overall, nighttime application of an OTC anhydrous AP containing an Aluminum Zirconium Trichlorohydrex Gly active ingredient does deliver statistically similar efficacy to a Prescription Aluminum Chloride AP.

• Additionally, the "soft solid" AP demonstrates the ability to deliver this efficacy without the key compliance negative (irritation) of current Prescription Aluminum Chloride APs.

METHODS

Clinical Test Protocol

Two clinical studies were designed to quantify the underarm wetness performance of an OTC anhydrous AP relative to a marketed prescription AP (6% Concentration). The panelists had product applied to their underarms (product application was randomized and blinded) every evening for 7 days (In the second study, the duration was extended to 10 days). Baseline sweat collection occurred on Day 1 before product was applied and another sweat collection occurred on Day 7. (In the second study, an additional measurement was taken at Day 10). The panelists were evaluated for irritation during each visit. If a panelist had an irritation score of 2 or above, product application was discontinued and the highest irritation score for that panelist was carried forward for the analysis. Even if application was discontinued, all subjects were eligible to participate in sweat collection regardless of treatment compliance and were considered in the analyses to provide an estimate representative of actual practice. Note that only the Prescription Aluminum Chloride AP usage led to an irritation score of 2 or above and required discontinuation.

Data Analysis

Mixed model techniques were used to analyze the gravimetric sweat data and a 95% confidence interval was constructed to assess non-inferiority. A boundary condition of 20% was used for the non-inferiority criteria because in a controlled, single product blind test study placed among females, consumers did not notice differences in level of sweat between products with clinically demonstrated differences of greater than 20%.

References


This work was funded by P&G Beauty